Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer

Shadi Ferdosi, Douglas S. Rehder, Paul Maranian, Erik P. Castle, Thai H. Ho, Harvey I. Pass, Daniel W. Cramer, Karen Anderson, Lei Fu, David E.C. Cole, Tao Le, Xifeng Wu, Chad Borges

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Glycans represent a promising but only marginally accessed source of cancer markers. We previously reported the development of a molecularly bottom-up approach to plasma and serum (P/S) glycomics based on glycan linkage analysis that captures features such as α2-6 sialylation, β1-6 branching, and core fucosylation as single analytical signals. Based on the behavior of P/S glycans established to date, we hypothesized that the alteration of P/S glycans observed in cancer would be independent of the tissue in which the tumor originated yet exhibit stage dependence that varied little between cancers classified on the basis of tumor origin. Herein, the diagnostic utility of this bottom-up approach as applied to lung cancer patients (n = 127 stage I; n = 20 stage II; n = 81 stage III; and n = 90 stage IV) as well as prostate (n = 40 stage II), serous ovarian (n = 59 stage III), and pancreatic cancer patients (n = 15 rapid autopsy) compared to certifiably healthy individuals (n = 30), nominally healthy individuals (n = 166), and risk-matched controls (n = 300) is reported. Diagnostic performance in lung cancer was stage-dependent, with markers for terminal (total) fucosylation, α2-6 sialylation, β1-4 branching, β1-6 branching, and outer-arm fucosylation most able to differentiate cases from controls. These markers behaved in a similar stage-dependent manner in other types of cancer as well. Notable differences between certifiably healthy individuals and case-matched controls were observed. These markers were not significantly elevated in liver fibrosis. Using a Cox proportional hazards regression model, the marker for α2-6 sialylation was found to predict both progression and survival in lung cancer patients after adjusting for age, gender, smoking status, and stage. The potential mechanistic role of aberrant P/S glycans in cancer progression is discussed.

Original languageEnglish (US)
Pages (from-to)543-558
Number of pages16
JournalJournal of Proteome Research
Volume17
Issue number1
DOIs
StatePublished - Jan 5 2018

Fingerprint

Polysaccharides
Plasmas
Serum
Neoplasms
Lung Neoplasms
Tumors
Glycomics
Liver
Hazards
Pancreatic Neoplasms
Proportional Hazards Models
Tissue
Liver Cirrhosis
Prostate
Autopsy
Smoking
Survival

Keywords

  • branching
  • cancer
  • fucosylation
  • glycans
  • plasma
  • progression
  • serum
  • sialylation
  • smoking
  • survival

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer. / Ferdosi, Shadi; Rehder, Douglas S.; Maranian, Paul; Castle, Erik P.; Ho, Thai H.; Pass, Harvey I.; Cramer, Daniel W.; Anderson, Karen; Fu, Lei; Cole, David E.C.; Le, Tao; Wu, Xifeng; Borges, Chad.

In: Journal of Proteome Research, Vol. 17, No. 1, 05.01.2018, p. 543-558.

Research output: Contribution to journalArticle

Ferdosi, Shadi ; Rehder, Douglas S. ; Maranian, Paul ; Castle, Erik P. ; Ho, Thai H. ; Pass, Harvey I. ; Cramer, Daniel W. ; Anderson, Karen ; Fu, Lei ; Cole, David E.C. ; Le, Tao ; Wu, Xifeng ; Borges, Chad. / Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer. In: Journal of Proteome Research. 2018 ; Vol. 17, No. 1. pp. 543-558.
@article{df337571c5084dc4ad058bfdeaf6154e,
title = "Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer",
abstract = "Glycans represent a promising but only marginally accessed source of cancer markers. We previously reported the development of a molecularly bottom-up approach to plasma and serum (P/S) glycomics based on glycan linkage analysis that captures features such as α2-6 sialylation, β1-6 branching, and core fucosylation as single analytical signals. Based on the behavior of P/S glycans established to date, we hypothesized that the alteration of P/S glycans observed in cancer would be independent of the tissue in which the tumor originated yet exhibit stage dependence that varied little between cancers classified on the basis of tumor origin. Herein, the diagnostic utility of this bottom-up approach as applied to lung cancer patients (n = 127 stage I; n = 20 stage II; n = 81 stage III; and n = 90 stage IV) as well as prostate (n = 40 stage II), serous ovarian (n = 59 stage III), and pancreatic cancer patients (n = 15 rapid autopsy) compared to certifiably healthy individuals (n = 30), nominally healthy individuals (n = 166), and risk-matched controls (n = 300) is reported. Diagnostic performance in lung cancer was stage-dependent, with markers for terminal (total) fucosylation, α2-6 sialylation, β1-4 branching, β1-6 branching, and outer-arm fucosylation most able to differentiate cases from controls. These markers behaved in a similar stage-dependent manner in other types of cancer as well. Notable differences between certifiably healthy individuals and case-matched controls were observed. These markers were not significantly elevated in liver fibrosis. Using a Cox proportional hazards regression model, the marker for α2-6 sialylation was found to predict both progression and survival in lung cancer patients after adjusting for age, gender, smoking status, and stage. The potential mechanistic role of aberrant P/S glycans in cancer progression is discussed.",
keywords = "branching, cancer, fucosylation, glycans, plasma, progression, serum, sialylation, smoking, survival",
author = "Shadi Ferdosi and Rehder, {Douglas S.} and Paul Maranian and Castle, {Erik P.} and Ho, {Thai H.} and Pass, {Harvey I.} and Cramer, {Daniel W.} and Karen Anderson and Lei Fu and Cole, {David E.C.} and Tao Le and Xifeng Wu and Chad Borges",
year = "2018",
month = "1",
day = "5",
doi = "10.1021/acs.jproteome.7b00672",
language = "English (US)",
volume = "17",
pages = "543--558",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer

AU - Ferdosi, Shadi

AU - Rehder, Douglas S.

AU - Maranian, Paul

AU - Castle, Erik P.

AU - Ho, Thai H.

AU - Pass, Harvey I.

AU - Cramer, Daniel W.

AU - Anderson, Karen

AU - Fu, Lei

AU - Cole, David E.C.

AU - Le, Tao

AU - Wu, Xifeng

AU - Borges, Chad

PY - 2018/1/5

Y1 - 2018/1/5

N2 - Glycans represent a promising but only marginally accessed source of cancer markers. We previously reported the development of a molecularly bottom-up approach to plasma and serum (P/S) glycomics based on glycan linkage analysis that captures features such as α2-6 sialylation, β1-6 branching, and core fucosylation as single analytical signals. Based on the behavior of P/S glycans established to date, we hypothesized that the alteration of P/S glycans observed in cancer would be independent of the tissue in which the tumor originated yet exhibit stage dependence that varied little between cancers classified on the basis of tumor origin. Herein, the diagnostic utility of this bottom-up approach as applied to lung cancer patients (n = 127 stage I; n = 20 stage II; n = 81 stage III; and n = 90 stage IV) as well as prostate (n = 40 stage II), serous ovarian (n = 59 stage III), and pancreatic cancer patients (n = 15 rapid autopsy) compared to certifiably healthy individuals (n = 30), nominally healthy individuals (n = 166), and risk-matched controls (n = 300) is reported. Diagnostic performance in lung cancer was stage-dependent, with markers for terminal (total) fucosylation, α2-6 sialylation, β1-4 branching, β1-6 branching, and outer-arm fucosylation most able to differentiate cases from controls. These markers behaved in a similar stage-dependent manner in other types of cancer as well. Notable differences between certifiably healthy individuals and case-matched controls were observed. These markers were not significantly elevated in liver fibrosis. Using a Cox proportional hazards regression model, the marker for α2-6 sialylation was found to predict both progression and survival in lung cancer patients after adjusting for age, gender, smoking status, and stage. The potential mechanistic role of aberrant P/S glycans in cancer progression is discussed.

AB - Glycans represent a promising but only marginally accessed source of cancer markers. We previously reported the development of a molecularly bottom-up approach to plasma and serum (P/S) glycomics based on glycan linkage analysis that captures features such as α2-6 sialylation, β1-6 branching, and core fucosylation as single analytical signals. Based on the behavior of P/S glycans established to date, we hypothesized that the alteration of P/S glycans observed in cancer would be independent of the tissue in which the tumor originated yet exhibit stage dependence that varied little between cancers classified on the basis of tumor origin. Herein, the diagnostic utility of this bottom-up approach as applied to lung cancer patients (n = 127 stage I; n = 20 stage II; n = 81 stage III; and n = 90 stage IV) as well as prostate (n = 40 stage II), serous ovarian (n = 59 stage III), and pancreatic cancer patients (n = 15 rapid autopsy) compared to certifiably healthy individuals (n = 30), nominally healthy individuals (n = 166), and risk-matched controls (n = 300) is reported. Diagnostic performance in lung cancer was stage-dependent, with markers for terminal (total) fucosylation, α2-6 sialylation, β1-4 branching, β1-6 branching, and outer-arm fucosylation most able to differentiate cases from controls. These markers behaved in a similar stage-dependent manner in other types of cancer as well. Notable differences between certifiably healthy individuals and case-matched controls were observed. These markers were not significantly elevated in liver fibrosis. Using a Cox proportional hazards regression model, the marker for α2-6 sialylation was found to predict both progression and survival in lung cancer patients after adjusting for age, gender, smoking status, and stage. The potential mechanistic role of aberrant P/S glycans in cancer progression is discussed.

KW - branching

KW - cancer

KW - fucosylation

KW - glycans

KW - plasma

KW - progression

KW - serum

KW - sialylation

KW - smoking

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85040174649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040174649&partnerID=8YFLogxK

U2 - 10.1021/acs.jproteome.7b00672

DO - 10.1021/acs.jproteome.7b00672

M3 - Article

VL - 17

SP - 543

EP - 558

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 1

ER -